Anti-SARS-CoV-2 Nanobody
COVID-19
PreclinicalActive
Key Facts
About Numaferm
Numaferm is a Hamburg-based biotech firm operating at the intersection of synthetic biology and biologics production. The company has developed two core technology platforms: Numascreen™ for high-diversity phage display-based lead discovery and Numatech™ for high-titer, cost-effective microbial expression. With an ISO 9001:2015 certified operation and a team of ~30 experts, Numaferm serves as a service provider and partner for pharmaceutical, agricultural, and industrial clients, aiming to democratize access to peptide and protein-based solutions. Its business model combines fee-for-service projects with technology licensing and process development partnerships.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |